ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
Company profile
Ticker
ZIVO
Exchange
Website
CEO
Andrew Dahl
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HEALTH ENHANCEMENT PRODUCTS INC, WESTERN GLORY HOLE INC
SEC CIK
Corporate docs
Subsidiaries
Health Enhancement Corporation • HEPI Pharmaceuticals, Inc. • Wellmetrix, LLC • Wellmetris, LLC • Zivo Biologic, Inc. • Zivo Bioscience, LLC • Zivo Zoologic, Inc. • ZIVOLife LLC ...
IRS number
870699977
ZIVO stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Feb 24
25-NSE
Exchange delisting
15 Feb 24
8-K
Unregistered Sales of Equity Securities
17 Jan 24
8-K
Unregistered Sales of Equity Securities
5 Jan 24
8-K
Unregistered Sales of Equity Securities
3 Jan 24
8-K
Unregistered Sales of Equity Securities
11 Dec 23
RW
Registration withdrawal request
1 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Nov 23
8-K
Entry into a Material Definitive Agreement
22 Nov 23
Latest ownership filings
SC 13D/A
STROME MEZZANINE FUND, LP
9 Apr 24
SC 13D
Maggiore Christopher D.
22 Jan 24
4
Alison A Cornell
4 Jan 24
4
Christopher D. Maggiore
2 Jan 24
4
Christopher D. Maggiore
14 Dec 23
4
MARK E STROME
30 Oct 23
SC 13D/A
STROME MEZZANINE FUND, LP
30 Oct 23
4
Alison A Cornell
14 Jun 23
4
Christopher D. Maggiore
14 Jun 23
4
Nola E Masterson
14 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.48 mm | 1.48 mm | 1.48 mm | 1.48 mm | 1.48 mm | 1.48 mm |
Cash burn (monthly) | (no burn) | 158.44 k | 524.13 k | 667.02 k | 656.51 k | 544.27 k |
Cash used (since last report) | n/a | 1.06 mm | 3.51 mm | 4.47 mm | 4.40 mm | 3.64 mm |
Cash remaining | n/a | 423.84 k | -2.02 mm | -2.98 mm | -2.91 mm | -2.16 mm |
Runway (months of cash) | n/a | 2.7 | -3.9 | -4.5 | -4.4 | -4.0 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 7 |
Closed positions | 5 |
Increased positions | 2 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 3.58 bn |
Total shares | 80.20 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Strome Mezzanine Fund | 78.58 mm | $11.37 mm |
Armistice Capital | 1.02 mm | $2.48 bn |
Geode Capital Management | 272.79 k | $660.15 mm |
Vanguard | 116.33 k | $281.52 mm |
Warberg Asset Management | 107.46 k | $64.47 mm |
Ayrton Capital | 48.85 k | $29.31 mm |
Verdence Capital Advisors | 20.00 k | $30.20 mm |
CVI | 16.11 k | $8.05 mm |
Citadel Advisors | 10.10 k | $5.05 mm |
BLK Blackrock | 5.02 k | $12.15 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 24 | Alison A Cornell | Common Stock | Buy | Acquire P | No | No | 1.2 | 41,666 | 50.00 k | 68,666 |
29 Dec 23 | Maggiore Christopher D. | Common Stock | Buy | Acquire P | No | No | 1.3 | 157,692 | 205.00 k | 336,816 |
13 Dec 23 | Maggiore Christopher D. | Common Stock | Buy | Acquire P | No | No | 1 | 45,000 | 45.00 k | 179,124 |
12 Jun 23 | Masterson Nola E | Nonstatutory Stock Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 2.79 | 21,756 | 60.70 k | 21,756 |
12 Jun 23 | Alison A Cornell | Nonstatutory Stock Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 2.79 | 21,756 | 60.70 k | 21,756 |
Press releases
ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
7 Feb 24
ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
23 Jan 24